[go: up one dir, main page]

BR0307016A - 3- (imidazolyl) -2-alkoxypropanoic acids - Google Patents

3- (imidazolyl) -2-alkoxypropanoic acids

Info

Publication number
BR0307016A
BR0307016A BR0307016-6A BR0307016A BR0307016A BR 0307016 A BR0307016 A BR 0307016A BR 0307016 A BR0307016 A BR 0307016A BR 0307016 A BR0307016 A BR 0307016A
Authority
BR
Brazil
Prior art keywords
imidazolyl
acids
alkyl
hydrogen
optionally substituted
Prior art date
Application number
BR0307016-6A
Other languages
Portuguese (pt)
Inventor
Charlotte Moira Norfo Allerton
David John Bull
Mark Edward Bunnage
Robert John Maguire
John Steele
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0201389A external-priority patent/GB0201389D0/en
Priority claimed from GB0202027A external-priority patent/GB0202027D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of BR0307016A publication Critical patent/BR0307016A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"áCIDOS 3-(IMIDAZOLIL)-2-ALCOXIPROPANóICOS". A presente invenção refere-se a novos compostos de acordo com a fórmula (I), em que n é 0-3, R^ 1^ é alquila C~ 1-6~, alquenila C~ 2-6~, ou alquinila C~ 2-6~ opcionalmente substituídas, heterociclo, heterociclo aromático, arila ou hidrogênio e R^ 2^, R^ 3^, R^ 4^, R^ 5^, R^ 6^, R^ 7^,R^ 8^ e R^ 9^ são independentemente selecionados, cada um, a partir de hidrogênio e alquila C~ 1-6~ opcionalmente substituída, ou R^ 5^ e R^ 8^ são uma cadeia de alquileno. Eles são úteis no tratamento de condições trombóticas e outras patrologias associadas com a deposição de fibrina."3- (IMIDAZOLYL) -2-ALCOXIPROPANOIC ACIDS". The present invention relates to novel compounds according to formula (I), wherein n is 0-3, R4 is C1-6 alkyl, C2-6 alkenyl, or C-alkynyl. Optionally substituted, 2-6-, heterocycle, aromatic heterocycle, aryl or hydrogen and R ^ 2 ^, R ^ 3 ^, R ^ 4 ^, R ^ 5 ^, R ^ 6 ^, R ^ 7 ^, R ^ 8 R 2 and R 9 are each independently selected from hydrogen and optionally substituted C 1-6 alkyl, or R 5 and R 8 are an alkylene chain. They are useful in treating thrombotic conditions and other conditions associated with fibrin deposition.

BR0307016-6A 2002-01-22 2003-01-10 3- (imidazolyl) -2-alkoxypropanoic acids BR0307016A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0201389A GB0201389D0 (en) 2002-01-22 2002-01-22 3-(imidazolyl)-2-alkoxypropanoic acids
GB0202027A GB0202027D0 (en) 2002-01-29 2002-01-29 3-(imidazolyl)-2-alkoxypropanoic acids
PCT/IB2003/000060 WO2003061652A1 (en) 2002-01-22 2003-01-10 3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors

Publications (1)

Publication Number Publication Date
BR0307016A true BR0307016A (en) 2004-11-03

Family

ID=27614792

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0307016-6A BR0307016A (en) 2002-01-22 2003-01-10 3- (imidazolyl) -2-alkoxypropanoic acids

Country Status (24)

Country Link
EP (1) EP1467731A1 (en)
JP (1) JP2005520811A (en)
KR (1) KR20040077775A (en)
CN (1) CN1620291A (en)
AP (1) AP2004003084A0 (en)
AR (1) AR038197A1 (en)
BR (1) BR0307016A (en)
CA (1) CA2472238A1 (en)
EA (1) EA200400716A1 (en)
EC (1) ECSP045200A (en)
HR (1) HRP20040659A2 (en)
IL (1) IL162677A0 (en)
IS (1) IS7310A (en)
MA (1) MA27167A1 (en)
MX (1) MXPA04006573A (en)
NO (1) NO20043457L (en)
OA (1) OA12756A (en)
PA (1) PA8563501A1 (en)
PE (1) PE20030929A1 (en)
PL (1) PL371487A1 (en)
TN (1) TNSN04121A1 (en)
TW (1) TW200302094A (en)
UY (1) UY27615A1 (en)
WO (1) WO2003061652A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005051384A1 (en) * 2003-11-25 2005-06-09 Pfizer Limited Stabilised pharmaceutical compositions
JP2008536923A (en) * 2005-04-18 2008-09-11 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト Use of TAFI inhibitors to enhance myocardial reperfusion and facilitate PCI
US20110213143A1 (en) 2008-10-29 2011-09-01 Taisho Pharmaceutical Co., Ltd. Compound having tafia inhibitory activity
US8987242B2 (en) 2008-12-05 2015-03-24 Merck Sharp & Dohme Corp. Morpholinone compounds as factor IXA inhibitors
EP2373634B1 (en) * 2008-12-05 2015-11-11 Mochida Pharmaceutical Co., Ltd. Morpholinone compounds as factor ixa inhibitors
EP2548872B1 (en) 2010-03-18 2016-09-28 Daiichi Sankyo Company, Limited Cyclopropanecarboxylic acid derivative
HUE035072T2 (en) * 2010-03-18 2018-05-02 Daiichi Sankyo Co Ltd Cycloalkyl-substituted imidazole derivative
US9834527B2 (en) 2013-06-10 2017-12-05 Sanofi Macrocyclic urea derivatives as inhibitors of TAFIa, their preparation and their use as pharmaceuticals
CN108883094A (en) 2016-03-29 2018-11-23 第三共株式会社 Inflammatory bowel Remedies for diseases in association
BR112020005174A2 (en) 2017-09-14 2020-11-10 Daiichi Sankyo Company,Limited compound that has cyclic structure

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9901572D0 (en) * 1999-05-03 1999-05-03 Astra Ab New compounds
HUP0303763A3 (en) * 2000-08-17 2004-06-28 Pfizer Substituted imidazoles as tafia inhibitors, process for their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
PA8563501A1 (en) 2004-08-31
EP1467731A1 (en) 2004-10-20
MXPA04006573A (en) 2004-10-04
EA200400716A1 (en) 2004-12-30
CA2472238A1 (en) 2003-07-31
WO2003061652A8 (en) 2004-09-10
NO20043457L (en) 2004-08-19
AP2004003084A0 (en) 2004-09-30
OA12756A (en) 2006-07-03
IS7310A (en) 2004-06-14
PL371487A1 (en) 2005-06-13
JP2005520811A (en) 2005-07-14
TNSN04121A1 (en) 2006-06-01
PE20030929A1 (en) 2003-11-05
MA27167A1 (en) 2005-01-03
IL162677A0 (en) 2005-11-20
HRP20040659A2 (en) 2004-10-31
KR20040077775A (en) 2004-09-06
WO2003061652A1 (en) 2003-07-31
AR038197A1 (en) 2005-01-05
ECSP045200A (en) 2004-08-27
TW200302094A (en) 2003-08-01
CN1620291A (en) 2005-05-25
UY27615A1 (en) 2003-08-29

Similar Documents

Publication Publication Date Title
NO20020725D0 (en) cell adhesion inhibitor
NO20065178L (en) Tienopyridinderivater
NO20050065L (en) Chemical connections
DE60132827D1 (en) METALLOCENE AND CATALYST COMPOSITIONS DERIVED BY YOU
DE60213452D1 (en) METALLOCENE AND METHOD FOR PRODUCING PROPYLENE POLYMERS
EP1254895A4 (en) Nitrogenous cyclic compounds and pharmaceutical compositions containing the same
BRPI0606740A2 (en) bis aryl and heteroaryl compounds substituted as selective 5ht2a antagonists
BR0307016A (en) 3- (imidazolyl) -2-alkoxypropanoic acids
BR0313917A (en) Antimicrobial Compositions
IN2012DN00758A (en)
DK1644389T3 (en) Pyrinidine compounds with phosphonate groups as antiviral nucleotide analogues
BR0307033A (en) 3- (imidazolyl) -2-aminopropanoic acids for use as tafi-a inhibitors for the treatment of thrombotic diseases
DE59509910D1 (en) Process for the preparation of alkylhydrogenchlorosilanes
BR0115996A (en) Sulfamidothienopyrimidines
NO20005301L (en) Pyrrolidines as inhibitors of neuraminidases
ATE440100T1 (en) PRENYL TRANSFERAS INHIBITORS
ATE279476T1 (en) SILICONE-CONTAINING COMPOSITIONS FOR THE TREATMENT OF WOOL MATERIALS
BR0317719A (en) Phosphoramide Derivatives
DE60013515D1 (en) 4-arylpiperidine derivatives for the treatment of pruritus
BRPI0805173A2 (en) functionalized monomers and functionalized elastic polymers made from them
ATE428687T1 (en) ORGANIC ACTIVATOR
BR9714436A (en) Process for the production of imidazole derivatives
DOP2003000564A (en) ACIDS 3- (IMIDAZOLIL) -2-ALCOXIPROPANOICOS
DE50206142D1 (en) PROCESS FOR THE PREPARATION OF 1,3-DISUBSTITUTED 2-NITROGUANIDINES
UY27616A1 (en) ACIDS 3 - (AMIDAZOLIL) - AMINOPROPANOICS

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4O, 5O, 6O E 7O ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2047 DE 30/03/2010.